Requiring country-of-origin labeling for dietary supplements would be redundant with good manufacturing practices and could raise prices without benefiting consumers, according to the Council for Responsible Nutrition
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
